Meglumine antimoniate warnings and precautions

Revision as of 03:42, 7 January 2014 by Gerald Chi (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Meglumine Antimoniate
GLUCANTIM® WHO Prescribing Information
Description
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Dosage and Administration
How Supplied

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Warnings and Precautions

A protein-rich diet should be provided throughout treatment and, where possible, iron depletion and other specific deficiencies should be corrected beforehand.

When possible, both the electrocardiogram and renal and hepatic function should be monitored throughout treatment. Dosage must be reduced should abnormalities occur.

Use in pregnancy

Safe use in pregnancy has not been established. However, because it is potentially fatal, visceral leishmaniasis should always be treated without delay.[1]

References

  1. "WHO Model Prescribing Information: Drugs Used in Parasitic Diseases - Second Edition: Protozoa: Leishmaniasis: Meglumine antimoniate and sodium stibogluconate".

Adapted from the FDA Package Insert.